West Pharmaceutical Services, Inc. Common Stock (WST)
216.26
-0.38 (-0.18%)
NYSE · Last Trade: May 19th, 12:17 PM EDT
Detailed Quote
Previous Close
216.64
Open
215.00
Bid
215.96
Ask
216.40
Day's Range
213.55 - 217.81
52 Week Range
187.43 - 355.66
Volume
152,705
Market Cap
15.64B
PE Ratio (TTM)
33.95
EPS (TTM)
6.4
Dividend & Yield
0.8400 (0.39%)
1 Month Average Volume
910,018
Chart
About West Pharmaceutical Services, Inc. Common Stock (WST)
West Pharmaceutical Services is a prominent global leader in the design and manufacturing of components and systems for the delivery of injectable drugs. The company specializes in producing high-quality materials such as stoppers, seals, and prefillable syringes, which are essential for the safe and efficient administration of pharmaceuticals. West Pharmaceutical Services partners with pharmaceutical and biotechnology companies to deliver innovative solutions that enhance drug efficacy and patient safety, focusing on advancing healthcare through its cutting-edge technologies and services. With a commitment to excellence and a strong emphasis on sustainability, West continually strives to improve the standards of drug delivery within the healthcare industry. Read More
NEW YORK, May 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against West Pharmaceutical Services, Inc. (“West” or the “Company”) (NYSE: WST). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Glancy Prongay & Murray LLP reminds investors of the upcoming July 7, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired West Pharmaceutical Services, Inc. (“West” or the “Company”) (NYSE: WST) common stock between February 16, 2023 and February 12, 2025, inclusive (the “Class Period”).
Law Offices of Howard G. Smith reminds investors of the upcoming July 7, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased West Pharmaceutical Services, Inc. (“West” or the “Company”) (NYSE: WST) common stock between February 16, 2023 and February 12, 2025, inclusive (the “Class Period”).
NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Avis Budget Group, Inc. (NASDAQ: CAR), Civitas Resources, Inc. (NYSE: CIVI), Open Lending Corporation (NASDAQ: LPRO), and West Pharmaceutical Services, Inc. (NYSE: WST). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
Curious about the top performers within the S&P500 index in the middle of the day on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of investors who purchased West Pharmaceutical Services, Inc. (“West” or the “Company”) (NYSE: WST) common stock between February 16, 2023 and February 12, 2025, inclusive (the “Class Period”). West investors have until July 7, 2025 to file a lead plaintiff motion.
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of common stock of West Pharmaceutical Services, Inc. (NYSE: WST) between February 16, 2023 and February 12, 2025. West describes itself as a “medical supplies company specializing in packaging components, containment solutions, and delivery systems for injectable drugs.”
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired West Pharmaceutical Services, Inc. (“West” or the “Company”) (NYSE: WST) common stock between February 16, 2023 and February 12, 2025, inclusive (the “Class Period”). West investors have until July 7, 2025 to file a lead plaintiff motion.
NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against West Pharmaceutical Services, Inc. (“West” or the “Company”) (NYSE: WST). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
A company with profits isn’t always a great investment.
Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased West Pharmaceutical Services, Inc. (“West” or the “Company”) (NYSE: WST) common stock between February 16, 2023 and February 12, 2025, inclusive (the “Class Period”). West investors have until July 7, 2025 to file a lead plaintiff motion.
Healthcare products company West Pharmaceutical Services (NYSE:WST) announced better-than-expected revenue in Q1 CY2025, but sales were flat year on year at $698 million. The company’s full-year revenue guidance of $2.96 billion at the midpoint came in 1.8% above analysts’ estimates. Its non-GAAP profit of $1.45 per share was 15.3% above analysts’ consensus estimates.
Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of West Pharmaceutical Services, Inc. (NYSE: WST) common stock between February 16, 2023 and February 12, 2025, both dates inclusive (the “Class Period”), have until July 7, 2025 to seek appointment as lead plaintiff of the West Pharmaceutical class action lawsuit. Captioned New England Teamsters Pension Fund v. West Pharmaceutical Services, Inc., No. 25-cv-02285 (E.D. Pa.), the West Pharmaceutical class action lawsuit charges West Pharmaceutical as well as certain of West Pharmaceutical’s current and former top executives with violations of the Securities Exchange Act of 1934.
NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against West Pharmaceutical Services, Inc. (“West” or the “Company”) (NYSE: WST). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns -
over the past six months, healthcare stocks have collectively shed 13.3%. This drawdown was worse than the S&P 500’s 5.8% fall.
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against West Pharmaceutical Services, Inc. (“West Pharmaceutical” or the “Company”) (NYSE:WST) in the United States District Court for the Eastern District of Pennsylvania on behalf of all persons and entities who purchased or otherwise acquired West Pharmaceutical securities between February 16, 2023, and February 12, 2025, both dates inclusive (the “Class Period”). Investors have until July 7, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of West Pharmaceutical Services, Inc. (“West” or the “Company”) (NYSE: WST) investors concerning the Company’s possible violations of the federal securities laws.
Law Offices of Howard G. Smith announces an investigation on behalf of West Pharmaceutical Services, Inc. (“West” or the “Company”) (NYSE: WST) investors concerning the Company’s possible violations of federal securities laws.
The Law Offices of Frank R. Cruz announces an investigation of West Pharmaceutical Services, Inc. (“West” or the “Company”) (NYSE: WST) on behalf of investors concerning the Company’s possible violations of federal securities laws.
The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of West Pharmaceutical Services, Inc. (NYSE: WST) common stock between February 16, 2023 and February 12, 2025, inclusive (the “Class Period”), have until July 7, 2025 to seek appointment as lead plaintiff of the West Pharmaceutical class action lawsuit. Captioned New England Teamsters Pension Fund v. West Pharmaceutical Services, Inc., No. 25-cv-02285 (E.D. Pa.), the West Pharmaceutical class action lawsuit charges West Pharmaceutical and certain of West Pharmaceutical’s current and former top executives with violations of the Securities Exchange Act of 1934.
